Nordwand Advisors LLC Has $51.30 Million Stock Position in Johnson & Johnson $JNJ

Nordwand Advisors LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 43.2% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 335,846 shares of the company’s stock after selling 255,838 shares during the period. Johnson & Johnson comprises about 8.1% of Nordwand Advisors LLC’s investment portfolio, making the stock its 2nd biggest holding. Nordwand Advisors LLC’s holdings in Johnson & Johnson were worth $51,300,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in JNJ. Chiron Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 31.4% in the 2nd quarter. Chiron Capital Management LLC now owns 2,970 shares of the company’s stock worth $454,000 after purchasing an additional 709 shares during the last quarter. Dorsey & Whitney Trust CO LLC increased its position in Johnson & Johnson by 0.4% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 99,987 shares of the company’s stock worth $15,273,000 after buying an additional 397 shares during the period. Root Financial Partners LLC lifted its stake in Johnson & Johnson by 40.1% in the second quarter. Root Financial Partners LLC now owns 10,752 shares of the company’s stock valued at $1,642,000 after buying an additional 3,078 shares during the last quarter. Landaas & Co. WI ADV boosted its holdings in shares of Johnson & Johnson by 30.1% during the second quarter. Landaas & Co. WI ADV now owns 2,398 shares of the company’s stock valued at $366,000 after acquiring an additional 555 shares during the period. Finally, Bulltick Wealth Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $341,000. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on JNJ shares. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a report on Monday, October 20th. Argus set a $210.00 price objective on Johnson & Johnson in a research report on Wednesday, October 15th. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Finally, Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $201.05.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $199.39 on Tuesday. The stock has a market cap of $480.38 billion, a price-to-earnings ratio of 19.25, a PEG ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $200.28. The stock’s 50 day moving average price is $186.24 and its 200 day moving average price is $170.46.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.6%. Johnson & Johnson’s payout ratio is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.